CCJ vs. NVS
CCJ (Cameco Corporation) and NVS (Novartis AG) are both stocks. CCJ operates in Uranium (Energy), while NVS operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, CCJ returned 25.74%/yr vs 11.14%/yr for NVS. At a 0.21 correlation, their price movements are largely independent.
Performance
CCJ vs. NVS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CCJ achieves a 10.35% return, which is significantly lower than NVS's 14.40% return. Over the past 10 years, CCJ has outperformed NVS with an annualized return of 25.74%, while NVS has yielded a comparatively lower 11.14% annualized return.
CCJ
- 1D
- 2.01%
- 1M
- -12.51%
- YTD
- 10.35%
- 6M
- 10.35%
- 1Y
- 52.94%
- 3Y*
- 47.60%
- 5Y*
- 36.72%
- 10Y*
- 25.74%
NVS
- 1D
- -0.55%
- 1M
- 2.22%
- YTD
- 14.40%
- 6M
- 18.98%
- 1Y
- 30.60%
- 3Y*
- 19.57%
- 5Y*
- 14.77%
- 10Y*
- 11.14%
CCJ vs. NVS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CCJ Cameco Corporation | 10.35% | 78.38% | 19.47% | 90.49% | 4.35% | 63.19% | 51.47% | -21.08% | 23.58% | -8.20% |
NVS Novartis AG | 14.40% | 46.95% | 0.02% | 16.14% | 8.06% | -3.65% | 3.34% | 13.92% | 5.95% | 19.42% |
Correlation
The correlation between CCJ and NVS is 0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.02 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.10 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.15 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.19 |
Correlation (All Time) Calculated using the full available price history since Nov 7, 1996 | 0.21 |
The correlation between CCJ and NVS shifts across timeframes, from 0.02 (1 year) to 0.21 (all time), reflecting how their relationship changes across market environments.
Fundamentals
CCJ:
$43.98B
NVS:
$293.28B
CCJ:
CA$1.49
NVS:
$6.99
CCJ:
94.45
NVS:
21.90
CCJ:
0.79
NVS:
1.48
CCJ:
17.37
NVS:
5.29
CCJ:
8.68
NVS:
7.62
CCJ:
CA$3.54B
NVS:
$56.05B
CCJ:
CA$1.04B
NVS:
$42.19B
CCJ:
CA$996.66M
NVS:
$22.40B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CCJ vs. NVS — Risk / Return Rank
CCJ
NVS
CCJ vs. NVS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Cameco Corporation (CCJ) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CCJ | NVS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.51 | ||
| Sortino ratioReturn per unit of downside risk | -0.42 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.26 | -0.06 |
| Calmar ratioReturn relative to maximum drawdown | 1.83 | 2.43 | -0.60 |
| Martin ratioReturn relative to average drawdown | 4.43 | 5.88 | -1.45 |
Loading charts...
Drawdowns
CCJ vs. NVS - Drawdown Comparison
The maximum CCJ drawdown since its inception was -87.53%, which is greater than NVS's maximum drawdown of -42.10%. Use the drawdown chart below to compare losses from any high point for CCJ and NVS.
Loading charts...
Drawdown Indicators
| CCJ | NVS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.53% | -42.10% | -45.43% |
Max Drawdown (1Y)Largest decline over 1 year | -29.13% | -12.65% | -16.48% |
Max Drawdown (3Y)Largest decline over 3 years | -40.01% | -19.95% | -20.06% |
Max Drawdown (5Y)Largest decline over 5 years | -40.01% | -20.42% | -19.59% |
Max Drawdown (10Y)Largest decline over 10 years | -57.22% | -26.03% | -31.19% |
Current DrawdownCurrent decline from peak | -24.71% | -6.46% | -18.25% |
Average DrawdownAverage peak-to-trough decline | -46.07% | -10.92% | -35.15% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.99% | 5.23% | +6.76% |
Volatility
CCJ vs. NVS - Volatility Comparison
Cameco Corporation (CCJ) has a higher volatility of 17.90% compared to Novartis AG (NVS) at 7.18%. This indicates that CCJ's price experiences larger fluctuations and is considered to be riskier than NVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CCJ | NVS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.90% | 7.18% | +10.72% |
Volatility (6M)Calculated over the trailing 6-month period | 39.91% | 14.96% | +24.95% |
Volatility (1Y)Calculated over the trailing 1-year period | 55.17% | 21.02% | +34.15% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 50.01% | 18.89% | +31.12% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.75% | 19.64% | +27.11% |
Dividends
CCJ vs. NVS - Dividend Comparison
CCJ's dividend yield for the trailing twelve months is around 0.17%, less than NVS's 3.12% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CCJ Cameco Corporation | 0.17% | 0.19% | 0.22% | 0.20% | 0.39% | 0.29% | 0.46% | 0.67% | 0.53% | 4.33% | 3.82% | 3.24% |
NVS Novartis AG | 3.12% | 2.90% | 3.84% | 3.44% | 3.70% | 3.86% | 3.22% | 3.03% | 3.47% | 3.24% | 3.73% | 3.10% |
Financials
CCJ vs. NVS - Financials Comparison
This section allows you to compare key financial metrics between Cameco Corporation and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CCJ vs. NVS - Profitability Comparison
CCJ - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cameco Corporation reported a gross profit of 291.00M and revenue of 847.55M. Therefore, the gross margin over that period was 34.3%.
NVS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a gross profit of 10.07B and revenue of 13.52B. Therefore, the gross margin over that period was 74.4%.
CCJ - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cameco Corporation reported an operating income of 154.28M and revenue of 847.55M, resulting in an operating margin of 18.2%.
NVS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported an operating income of 4.24B and revenue of 13.52B, resulting in an operating margin of 31.3%.
CCJ - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cameco Corporation reported a net income of 131.09M and revenue of 847.55M, resulting in a net margin of 15.5%.
NVS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a net income of 3.16B and revenue of 13.52B, resulting in a net margin of 23.3%.
Frequently Asked Questions
CCJ and NVS have a correlation of 0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CCJ has higher volatility (17.90%) compared to NVS (7.18%). In terms of maximum drawdown, CCJ dropped -87.53% vs NVS's -42.10%.
NVS currently has the higher Sharpe Ratio (1.47 vs 0.96), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CCJ and NVS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer